A new paper published by researchers at Fox Chase Cancer Center highlights the case of a patient who was diagnosed with adenoid cystic carcinoma (ACC) after a molecular panel identified the presence of an atypical fusion gene. The case underscores the importance of molecular testing in correctly diagnosing certain cancers, said first author Shuanzeng “Sam” Wei, MD, PhD, an Associate Professor in the Department of Pathology and Medical Director of the Clinical Genomics Laboratory at Fox Chase. He said the team published their case study to raise awareness that the absence of the typical MYB/MYBL1 fusion genes does not rule out ACC and that the novel NFIB fusion gene can also be diagnostic.

Designing an AI tool to support healthy .

The findings could enable more efficient production of the chemotherapeutic Taxol.

The Calibr-Skaggs Institute for Innovative Medicines, the drug development division of Scripps Research, today announced a milestone in cancer treatment with the dosing of the first patient in a phase 1 trial (NCT06878248) evaluating CLBR001 + ABBV-461, a modular, switchable chimeric antigen receptor T cell (sCAR-T) therapy in patients with advanced or metastatic breast cancer who have no suitable treatment options. This is the first study of the sCAR-T platform in solid tumors.

A new study using one of the world’s largest cancer registries shows that patient outcomes can be significantly impacted depending on when colorectal cancer (CRC) is diagnosed related to other cancers.